|
gptkbp:instanceOf
|
gptkb:drug
biologic medication
|
|
gptkbp:approvedBy
|
1993
|
|
gptkbp:ATCCode
|
gptkb:L03AB08
|
|
gptkbp:brand
|
gptkb:Betaseron
gptkb:Extavia
|
|
gptkbp:CASNumber
|
105857-23-6
|
|
gptkbp:contraindication
|
gptkb:liver_disease
severe depression
|
|
gptkbp:drugClass
|
gptkb:insulin
|
|
gptkbp:eliminationHalfLife
|
5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon beta-1b
|
|
gptkbp:indication
|
clinically isolated syndrome
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bayer
|
|
gptkbp:mechanismOfAction
|
immunotherapy
|
|
gptkbp:molecularWeight
|
approximately 18.5 kDa
|
|
gptkbp:origin
|
Escherichia coli expression system
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:relatedTo
|
gptkb:interferon_beta-1a
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:depression
injection site reaction
flu-like symptoms
liver enzyme elevation
|
|
gptkbp:UNII
|
GOL4793W1G
|
|
gptkbp:usedFor
|
multiple sclerosis
relapsing-remitting multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Betaseron
|
|
gptkbp:bfsLayer
|
6
|